216761

SoSe 22: The Drug Discovery Process in the Pharmaceutical Industry – From Hit to Clinical Candidate (part 2)

Roman Hillig, Holger Steuber

Information for students

Powerpoint with voice-over and/or videoconference at the regular time. The seminar will be presented in English. Students can participate in the two parts of this seminar series (part I in WS and part II in SS) in any sequence. close

Comments

Comment: Drug discovery is a highly interdisciplinary process which involves project teams of pharmacologists, medicinal chemists, protein chemists/molecular biologists, structural biologists and computational chemists. The lecture series will provide an introduction to the drug discovery process as run in the pharmaceutical industry, from target identification and validation, via hit finding methods and the hit-to-lead process, to lead optimization, development and clinical studies. Emphasis will be on the contributions which protein crystallography and further biophysical methods (such as NMR, ITC and SPR) can make during target selection, hit prioritization and lead optimization. In addition, typical target families such as protein kinases will be discussed in the context of available crystal structures, and co-complex crystal structures with lead and drug molecules will be analyzed in detail: How do drug molecules interact with their target proteins, and what can we learn from their optimization process? The aim of the course is to develop an understanding of the molecular mechanisms of drug discovery. Kontakt: Dr. R. Hillig: roman.hillig@nuvisan.com, Dr. H. Steuber: holger.steuber@nuvisan.com Content: 1. Introduction; 2. Protein-Ligand Interactions; 3. Target Class: Protein Kinases; 4. Hit-to-Lead and Lead Optimization; 5. ADMEtox; 6. Target Class: GPCRs; 7. PROTACs; 8. Chemical Biology close